
WHAT IS CLAIMED IS

1. A solid form of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione:



or a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or clathrate thereof, having an X-ray powder diffraction pattern comprising:

peaks at approximately 14.6 °2θ, 15.6 °2θ, 16.7 °2θ, 21.9 °2θ and 30.0 °2θ;
peaks at approximately 10.6 °2θ, 14.7 °2θ, 19.1 °2θ and 25.9 °2θ;
peaks at approximately 10.8 °2θ, 15.1 °2θ, 25.1 °2θ and 26.6 °2θ;
peaks at approximately 16.7 °2θ, 21.7 °2θ, 21.9 °2θ and 25.8 °2θ;
peaks at approximately 7.3 °2θ, 14.6 °2θ, 22.0 °2θ, 30.0 °2θ and 37.0 °2θ;
peaks at approximately 14.5 °2θ, 15.7 °2θ, 22.7 °2θ and 29.9 °2θ; or
peaks at approximately 8.6 °2θ, 13.1 °2θ, 20.5 °2θ and 26.3 °2θ.

2. The solid form of claim 1, which is a solid form of a hydrochloride salt of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione and has an X-ray powder diffraction pattern comprising peaks at about 8.6, 13.1, 20.5 and 26.3 degrees 2θ.

~~3. The solid form of claim 1 or 2, which is amorphous.~~

~~4. The solid form of claim 1 or 2, which is crystalline.~~

~~5~~3. The solid form of claim 2, having an X-ray powder diffraction pattern substantially as shown in FIG. 18.

~~6. The solid form of claim 2, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 13.1, 20.5 and 26.3 degrees 2θ.~~

~~7~~4. The solid form of claim 2, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 11.3, 13.1, 15.3, 17.3, 20.5, 22.7, 23.6, 26.3 and 31.4 degrees 2θ.

~~8~~5. The solid form of any one of claims 2-~~7~~4, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 276 °C.

~~9~~6. The solid form of any one of claims 2-~~8~~5, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.5% when heated from about 25 °C to about 150 °C.

~~10~~7. The solid form of any one of claims 2-~~9~~6, which is anhydrous.

~~11~~8. The solid form of any one of claims 2-~~10~~7, which exhibits a mass increase of less than about 0.5% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~12~~9. The solid form of any one of claims 2-~~11~~8, which is substantially nonhygroscopic.

~~13~~10. The solid form of any one of claims 2-~~12~~9, which is stable upon exposure to about 40 °C and about 75% relative humidity for about 4 weeks.

~~14~~11. The solid form of any one of claims 2-~~13~~10, wherein the molar ratio of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione to hydrochloride is from about 0.1 to about 10.

~~15~~12. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 1.

~~16~~13. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 14.6, 15.6, 16.7, 21.9 and 30.0 degrees 2θ.

~~17~~14. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 9.2, 13.4, 14.0, 14.6, 15.6, 16.7, 18.5, 21.9, 22.7, 24.8, 28.1, 30.0 and 37.0 degrees 2θ.

~~18~~15. The solid form of any one of claims ~~15-17~~ 12-14, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 282 °C.

~~19~~16. The solid form of any one of claims ~~15-18~~ 12-15, having a thermal gravimetric analysis plot comprising a mass loss of less than about 6% when heated from about 25 °C to about 150 °C.

~~20~~17. The solid form of any one of claims ~~15-19~~ 12-16, which exhibits a mass increase of less than or equal to about 6% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~21~~18. The solid form of any one of claims ~~15-20~~ 12-17, which is hydrated.

~~22~~19. The solid form of claim ~~21~~ 18, which the crystal lattice of the solid form comprises about one molar equivalent of water per mole of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione.

~~23~~20. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 4.

~~24~~21. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 14.7, 19.1 and 25.9 degrees 2θ.

~~25~~22. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 11.4, 12.6, 13.7, 14.7, 19.1, 20.3, 20.9, 21.2, 22.9, 24.9, 25.3, 25.9, 26.9, 29.5 and 33.8 degrees 2θ.

~~26~~23. The solid form of any one of claims ~~23-25~~ 20-22, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 279 °C.

~~27~~24. The solid form of any one of claims ~~23-26~~ 20-23, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.1% when heated from about 25 °C to about 150 °C.

~~28~~25. The solid form of any one of claims ~~23-27~~ 20-24, which exhibits a mass increase of less than about 0.2% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~29~~26. The solid form of any one of claims ~~23-28~~ 20-25, which is unsolvated.

~~30~~27. The solid form of any one of claims ~~23-29~~ 20-26, which is substantially nonhygroscopic.

~~31~~28. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 7.

~~32~~29. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.8, 15.1, 25.1 and 26.6 degrees 2θ.

~~33~~30. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.8, 11.9, 15.1, 18.8, 19.2, 19.3, 22.0, 24.9, 25.1, 26.6 and 29.2 degrees 2θ.

~~34~~31. The solid form of any one of claims ~~31-33~~ 28-30, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 281 °C.

~~35~~32. The solid form of any one of claims ~~31-34~~ 28-31, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.1% when heated from about 25 °C to about 150 °C.

~~36~~33. The solid form of any one of claims ~~31-35~~ 28-32, which exhibits a mass increase of less than about 0.2% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~37~~34. The solid form of any one of claims ~~31-38~~ 28-33, which is unsolvated.

~~38~~35. The solid form of any one of claims ~~31-37~~ 28-34, which is substantially nonhygroscopic.

~~39~~36. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 10.

~~40~~37. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 16.7, 21.7, 21.9 and 25.8 degrees 2θ.

~~41~~38. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 14.0, 14.6, 15.7, 16.3, 16.7, 18.8, 21.7, 21.9, 24.8, 25.1, 25.8, 28.1 and 28.6 degrees 2θ.

~~42~~39. The solid form of any one of claims ~~39-41~~ 36-38, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 283 °C.

~~43~~40. The solid form of any one of claims ~~39-42~~ 36-39, having a thermal gravimetric analysis plot comprising a mass loss of less than about 4% when heated from about 25 °C to about 150 °C.

~~44~~41. The solid form of any one of claims ~~39-43~~ 36-40, which exhibits a mass increase of less than or equal to about 6% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~45~~42. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 13.

~~46~~43. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.3, 14.6, 22.0, 30.0 and 37.0 degrees 2θ.

~~47~~44. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.3, 9.3, 12.2, 14.0, 14.6, 15.7, 16.8, 21.0, 22.0, 22.7, 29.4, 30.0 and 37.0 degrees 2θ.

~~48~~45. The solid form of any one of claims ~~45-47~~ 42-44, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 279 °C.

~~49~~46. The solid form of any one of claims ~~45-48~~ 42-45, having a thermal gravimetric analysis plot comprising a mass loss of less than about 6% when heated from about 25 °C to about 150 °C.

~~50~~47. The solid form of any one of claims ~~45-49~~ 42-46, which exhibits a mass increase of less than about 0.5% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~51~~48. The solid form of any one of claims ~~45-50~~ 42-47, which is hydrated.

~~52~~49. The solid form of any one of claims ~~45-51~~ 42-48, which is substantially nonhygroscopic.

~~53~~50. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 16.

~~54~~51. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 14.5, 15.7, 22.7 and 29.9 degrees 2θ.

~~55~~52. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.2, 9.1, 14.5, 15.7, 16.8, 18.3, 21.9, 22.7, 29.9 and 36.9 degrees 2θ.

~~56~~53. The solid form of any one of claims ~~53-55~~ 50-52, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 267 °C.

~~57~~54. The solid form of any one of claims ~~53-56~~ 50-53, which is hydrated.

~~58~~55. A mixture comprising two or more solid forms selected from the solid forms of any one of claims 1-~~58~~54.

~~59~~56. A pharmaceutical composition comprising the solid form of any one of claims 1-~~58~~54 or the mixture of claim 55 and a pharmaceutical acceptable carrier, diluent or excipient.

~~60~~57. The pharmaceutical composition of claim ~~59~~ 56, wherein the composition is formulated for oral, parenteral, or intravenous administration.

~~61~~58. The pharmaceutical composition of claim ~~59~~ 56 or ~~60~~ 57, wherein the composition is formulated as a single unit dosage form.

~~62~~59. The pharmaceutical composition of claim ~~61~~ 58, wherein the ~~oral~~ dosage form is a tablet or capsule.

~~63~~60. Use of a solid form of any one of claims 1 to ~~62~~ 54, a mixture of claim 55, or a composition of any one of claims 56 to 59 in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, and a TNFα related disorder.

~~64~~61. The use of claim ~~63~~ 60, further comprising administering a second active agent.